Some Hodgkin's lymphoma patients respond well to treatment while others relapse. Randy Gascoyne, a hematopathologist and researcher at the British Columbia Cancer Agency, and his colleagues wanted to know why that is. Genome Technology's Christie Rizk spoke to Gascoyne to discuss his recent study, published in the New England Journal of Medicine. What follows is an excerpt of their conversation, edited for space and clarity.
Genome Technology: Why did you take this approach to studying Hodgkin's disease?